Axonics Modulation Technologies gathers $14.5 mln

Irvine, California-based Axonics Modulation Technologies Inc, a developer of the first rechargeable sacral neuromodulation system for the treatment of urinary and fecal dysfunction, has closed $14.5 million in the first close of its Series C financing. The investors included Edmond de Rothschild Investment Partners, Advent Life Sciences, Cormorant Asset Management, Legend Capital and NeoMed Management.

Source: Press Release